There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cathepsin B

Cathepsin B

Brief Information

Name:Cathepsin B
Target Synonym:CPSB,APPS,APP secretase,CTSB,Cathepsin B1,Cysteine Protease,EC,EC 3.4.22,RECEUP,EC:,Epididymis Secretory Sperm Binding Protein,Cathepsin B,Amyloid Precursor Protein Secretase
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CTB-H5222 Human Human Cathepsin B / CTSB Protein, His Tag (active enzyme)

Synonym Name



Cathepsin B (CTSB) is also known as APP secretase (APPS) and CPSB, is an enzymatic protein belonging to the peptidase C1 family. Cathepsin B / CTSB is synthesized as a preproenzyme. Following removal of the signal peptide, the inactive proenzyme undergoes further modifications including removal of the pro region to result in the active enzyme. The catalytic activity of Cathepsin B / APPS contains: Hydrolysis of proteins with broad specificity for peptide bonds; Preferentially cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates (thus differing from cathepsin L); In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. As a thiol protease, cathepsin B / CPSB is believed to participate in intracellular degradation and turnover of proteins and has also been implicated in tumor invasion and metastasis. Overexpression of cathepsin B has been associated with esophageal adenocarcinoma and other tumors.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aoxistatin AB-007; E-64-d Phase 3 Clinical Taisho Pharmaceutical Holdings Co Ltd Muscular Dystrophies Details
VBY-376 VBY-376 Phase 1 Clinical Virobay Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Hepatitis C, Chronic Details
AL-101 AL-101; BMS-906024 Phase 2 Clinical Bristol-Myers Squibb Company Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
BMS-986115 AL-102; BMS-986115 Phase 3 Clinical Bristol-Myers Squibb Company Fibromatosis, Aggressive; Hematologic Neoplasms; Neoplasms; Multiple Myeloma Details

This web search service is supported by Google Inc.